Novartis Receives FDA Approval for Pluvicto® to Treat Prostate Cancer at Earlier Stages
In a significant advancement for prostate cancer treatment, the U.S. Food and Drug Administration (FDA) has approved Novartis' radioligand therapy, Pluvicto® (lutetium Lu 177 vipivotide tetraxetan), for an earlier-stage application in patients diagnosed with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC). This groundbreaking decision, announced on March 28, 2025, allows for Pluvicto's use at an earlier phase, following treatment with one androgen receptor pathway inhibitor (ARPI) and before the initiation of chemotherapy. This regulatory change is expected to substantially expand the pool of patients eligible for this innovative therapy, nearly tripling the number of individuals who can benefit from it.
The approval is grounded in data from the Phase III PSMAfore trial, which demonstrated that Pluvicto significantly reduces the risk of disease progression or death by an impressive 59% compared to changes made in ARPI treatments. Additionally, it more than doubled median radiographic progression-free survival (rPFS), from 5.6 months to 11.6 months. These findings illustrate the potential of Pluvicto to alter the treatment landscape for patients who have experienced disease progression on previous therapies.
Dr. Michael Morris, an esteemed figure in prostate cancer oncology at Memorial Sloan Kettering Cancer Center, emphasized the importance of this development, stating, "The earlier indication for Pluvicto could really change our treatment paradigms for patients with mCRPC." By allowing this targeted therapy earlier in the treatment process, clinicians can offer a more effective option for managing prostate cancer that diverges from previous standard treatments like ARPI.
The implications of this approval can be profound, as nearly half of the patients with mCRPC do not live enough to qualify for a second treatment option. Thus, implementing Pluvicto sooner provides an essential opportunity to improve patient outcomes. The study not only highlighted improved survival rates but also reinforced the therapy's favorable safety profile. Most adverse effects reported were primarily Grade 1-2, including dry mouth, fatigue, nausea, and constipation, suggesting that Pluvicto can be administered with manageable side effects.
The approval comes at a critical time, as prostate cancer remains a leading cause of cancer deaths among men in the U.S., accounting for over 35,000 deaths annually. As the incidence of prostate cancer continues to rise, innovative treatments like Pluvicto are needed more than ever to provide effective options to healthcare providers and patients searching for ways to navigate the challenges of mCRPC.
Gina Carithers, CEO and President of the Prostate Cancer Foundation, remarked on the significance of this approval for patients and their families, highlighting that it represents more than just an additional treatment; it stands as a beacon of hope amid the uncertainty they face in their treatment journeys.
With the expanded approval of Pluvicto, nearly three times as many patients may engage with this promising treatment, underscoring the necessity of innovative therapies that can reshape cancer care. Victor Bultó, President of Novartis US, articulated the company's pledge to ensure that patients have access to this revolutionary treatment soon after diagnosis.
Novartis has committed to enhancing patient access through a robust infrastructure and has established multiple RLT treatment facilities across the U.S., ensuring timely delivery of Pluvicto to treatment sites. With the launch of the Novartis RLT Institute, the company aims to educate healthcare providers about radiation safety and streamline the integration of radioligand therapies into clinical practice.
As this treatment landscape evolves, Novartis is also investigating Pluvicto's applications in earlier disease stages, expanding beyond mCRPC to potentially enhance outcomes for patients with metastatic hormone-sensitive prostate cancer. This ambitious research direction emphasizes the company's dedication to continuous improvement in prostate cancer management and its willingness to innovate this vital space in oncology.
The approval is grounded in data from the Phase III PSMAfore trial, which demonstrated that Pluvicto significantly reduces the risk of disease progression or death by an impressive 59% compared to changes made in ARPI treatments. Additionally, it more than doubled median radiographic progression-free survival (rPFS), from 5.6 months to 11.6 months. These findings illustrate the potential of Pluvicto to alter the treatment landscape for patients who have experienced disease progression on previous therapies.
Dr. Michael Morris, an esteemed figure in prostate cancer oncology at Memorial Sloan Kettering Cancer Center, emphasized the importance of this development, stating, "The earlier indication for Pluvicto could really change our treatment paradigms for patients with mCRPC." By allowing this targeted therapy earlier in the treatment process, clinicians can offer a more effective option for managing prostate cancer that diverges from previous standard treatments like ARPI.
The implications of this approval can be profound, as nearly half of the patients with mCRPC do not live enough to qualify for a second treatment option. Thus, implementing Pluvicto sooner provides an essential opportunity to improve patient outcomes. The study not only highlighted improved survival rates but also reinforced the therapy's favorable safety profile. Most adverse effects reported were primarily Grade 1-2, including dry mouth, fatigue, nausea, and constipation, suggesting that Pluvicto can be administered with manageable side effects.
The approval comes at a critical time, as prostate cancer remains a leading cause of cancer deaths among men in the U.S., accounting for over 35,000 deaths annually. As the incidence of prostate cancer continues to rise, innovative treatments like Pluvicto are needed more than ever to provide effective options to healthcare providers and patients searching for ways to navigate the challenges of mCRPC.
Gina Carithers, CEO and President of the Prostate Cancer Foundation, remarked on the significance of this approval for patients and their families, highlighting that it represents more than just an additional treatment; it stands as a beacon of hope amid the uncertainty they face in their treatment journeys.
With the expanded approval of Pluvicto, nearly three times as many patients may engage with this promising treatment, underscoring the necessity of innovative therapies that can reshape cancer care. Victor Bultó, President of Novartis US, articulated the company's pledge to ensure that patients have access to this revolutionary treatment soon after diagnosis.
Novartis has committed to enhancing patient access through a robust infrastructure and has established multiple RLT treatment facilities across the U.S., ensuring timely delivery of Pluvicto to treatment sites. With the launch of the Novartis RLT Institute, the company aims to educate healthcare providers about radiation safety and streamline the integration of radioligand therapies into clinical practice.
As this treatment landscape evolves, Novartis is also investigating Pluvicto's applications in earlier disease stages, expanding beyond mCRPC to potentially enhance outcomes for patients with metastatic hormone-sensitive prostate cancer. This ambitious research direction emphasizes the company's dedication to continuous improvement in prostate cancer management and its willingness to innovate this vital space in oncology.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.